Oppenheimer Begins Coverage on Pulse Biosciences (NASDAQ:PLSE)

Investment analysts at Oppenheimer began coverage on shares of Pulse Biosciences (NASDAQ:PLSE - Get Free Report) in a note issued to investors on Monday,Briefing.com Automated Import reports. The firm set an "outperform" rating and a $22.00 price target on the stock. Oppenheimer's price objective would indicate a potential upside of 48.69% from the stock's current price.

Separately, Wall Street Zen upgraded shares of Pulse Biosciences to a "sell" rating in a report on Monday, March 31st.

Pulse Biosciences Trading Down 3.4%

PLSE stock opened at $14.80 on Monday. Pulse Biosciences has a 1-year low of $13.05 and a 1-year high of $25.00. The business's 50-day moving average price is $16.45 and its two-hundred day moving average price is $17.52.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.25) earnings per share for the quarter.

Insider Activity

In other news, CTO Darrin Uecker sold 15,000 shares of the company's stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $16.40, for a total transaction of $246,000.00. Following the completion of the transaction, the chief technology officer directly owned 137,872 shares of the company's stock, valued at $2,261,100.80. This represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 71.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Pulse Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC boosted its position in Pulse Biosciences by 98.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company's stock worth $29,000 after acquiring an additional 838 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Pulse Biosciences by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 149,206 shares of the company's stock worth $2,598,000 after purchasing an additional 1,092 shares in the last quarter. AlphaQuest LLC lifted its position in shares of Pulse Biosciences by 68.0% in the first quarter. AlphaQuest LLC now owns 3,116 shares of the company's stock worth $50,000 after purchasing an additional 1,261 shares in the last quarter. Rhumbline Advisers boosted its holdings in Pulse Biosciences by 6.3% during the first quarter. Rhumbline Advisers now owns 27,375 shares of the company's stock worth $440,000 after purchasing an additional 1,614 shares during the last quarter. Finally, Farther Finance Advisors LLC grew its position in Pulse Biosciences by 24.6% in the first quarter. Farther Finance Advisors LLC now owns 8,998 shares of the company's stock valued at $143,000 after purchasing an additional 1,778 shares in the last quarter. Institutional investors and hedge funds own 76.95% of the company's stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.